Circulating DNA in Esophageal Cancer—Utility Beyond the Prognostic Application
Menée à partir de 478 échantillons plasmatiques prélevés sur 147 patients atteints d'un carcinome épidermoïde de l'oesophage de stade localement avancé ou métastatique, cette étude met en évidence l'intérêt de l'ADN tumoral circulant pour établir un pronostic
In this issue of JAMA Surgery, Ng and colleagues have published an impressive and ambitious study investigating the clinical implications of longitudinal sampling of circulating tumor DNA (ctDNA) in patients with esophageal squamous cell carcinoma. There are several key findings that stand out in this comprehensive study. First is the remarkable mean (SD) lead time of 211 (36) days by which ctDNA positivity preceded disease recurrence compared with conventional cross-sectional imaging. While the trend was attenuated among patients treated palliatively, the results are in keeping with the pooled sensitivity for disease recurrence of 71.0% (95% CI, 55.7-82.6) described in a recent meta-analysis.
JAMA Surgery , éditorial, 2022